# FDA Inspection 1122926 - Karyopharm Therapeutics Inc. - February 28, 2020

Source: https://www.keypedia.com/records/fda_inspections/karyopharm-therapeutics-inc/8cba540f-91bc-4e5e-a927-2ae826e4537b
Source feed: FDA_Inspections

> FDA Inspection 1122926 for Karyopharm Therapeutics Inc. on February 28, 2020. Classification: No Action Indicated (NAI).

---

## Details

- Record Type: FDA Inspection
- Inspection ID: 1122926
- Company Name: Karyopharm Therapeutics Inc.
- Inspection Date: 2020-02-28
- Classification: No Action Indicated (NAI)
- Project Area: Bioresearch Monitoring
- Product Type: Drugs
- Office Name: Center for Drug Evaluation and Research

## Related Documents

- [FDA Inspection 1202243 - 2023-03-15](https://www.keypedia.com/records/fda_inspections/karyopharm-therapeutics-inc/9d7366f8-e70e-4af3-ba5a-8a9cbb9083f8)
- [FDA Inspection 1009153 - 2017-02-08](https://www.keypedia.com/records/fda_inspections/karyopharm-therapeutics-inc/8eb40be4-18ba-41d3-b5de-ba4c4b35c3b5)

Company: https://www.keypedia.com/companies/karyopharm-therapeutics-inc/28ffa225-b02c-40a0-8662-5bed25336a5a

Office: https://www.keypedia.com/offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c